BioLine RX LtdNASDAQ:BLRXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.6100
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.6100/ 3
- Ask / Lots0.6246/ 70
- Open / Previous Close0.5900 / 0.6100
- Day Range
- 52 Week Range
- Volume414,565
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BLRX |
|---|---|---|
| 09:32 ET | 3231 | 0.59 |
| 09:34 ET | 9701 | 0.61 |
| 09:36 ET | 15074 | 0.6 |
| 09:38 ET | 100 | 0.6025 |
| 09:39 ET | 6822 | 0.6 |
| 09:43 ET | 1500 | 0.6002 |
| 09:48 ET | 22100 | 0.6 |
| 09:50 ET | 6007 | 0.618 |
| 09:52 ET | 1900 | 0.605 |
| 09:54 ET | 100 | 0.6125 |
| 09:59 ET | 1800 | 0.609 |
| 10:01 ET | 730 | 0.62 |
| 10:03 ET | 1400 | 0.62 |
| 10:10 ET | 1900 | 0.615 |
| 10:12 ET | 6000 | 0.615 |
| 10:14 ET | 2289 | 0.62 |
| 10:17 ET | 3500 | 0.6175 |
| 10:21 ET | 3300 | 0.63 |
| 10:24 ET | 1015 | 0.628 |
| 10:26 ET | 319 | 0.625899 |
| 10:28 ET | 540 | 0.62305 |
| 10:37 ET | 1300 | 0.6231 |
| 10:39 ET | 8300 | 0.6201 |
| 10:42 ET | 500 | 0.6201 |
| 10:44 ET | 1025 | 0.6201 |
| 10:46 ET | 9900 | 0.6231 |
| 10:48 ET | 1000 | 0.626 |
| 10:57 ET | 22300 | 0.62 |
| 11:00 ET | 20097 | 0.6155 |
| 11:06 ET | 200 | 0.6156 |
| 11:08 ET | 100 | 0.6154 |
| 11:20 ET | 10000 | 0.6101 |
| 11:22 ET | 1500 | 0.6129 |
| 11:27 ET | 100 | 0.6129 |
| 11:31 ET | 16300 | 0.61 |
| 11:42 ET | 1000 | 0.6113 |
| 11:45 ET | 3590 | 0.607249 |
| 11:47 ET | 1000 | 0.6 |
| 11:49 ET | 1500 | 0.6 |
| 11:56 ET | 100 | 0.61 |
| 12:12 ET | 100 | 0.6101 |
| 12:20 ET | 45628 | 0.6158 |
| 12:34 ET | 800 | 0.62462 |
| 12:36 ET | 17000 | 0.62 |
| 12:38 ET | 7572 | 0.6044 |
| 12:56 ET | 100 | 0.6199 |
| 12:59 ET | 201 | 0.6101 |
| 01:03 ET | 300 | 0.615049 |
| 01:10 ET | 24000 | 0.6 |
| 01:12 ET | 190 | 0.6099 |
| 01:15 ET | 28925 | 0.6051 |
| 01:17 ET | 2000 | 0.6001 |
| 01:30 ET | 900 | 0.6002 |
| 01:32 ET | 12000 | 0.6002 |
| 01:33 ET | 1900 | 0.6002 |
| 01:46 ET | 6100 | 0.6001 |
| 02:09 ET | 100 | 0.61 |
| 02:20 ET | 666 | 0.601755 |
| 02:29 ET | 100 | 0.61 |
| 02:36 ET | 8200 | 0.61 |
| 02:38 ET | 2150 | 0.61 |
| 02:54 ET | 100 | 0.61 |
| 02:56 ET | 200 | 0.61 |
| 03:07 ET | 100 | 0.609899 |
| 03:09 ET | 100 | 0.6099 |
| 03:23 ET | 100 | 0.61 |
| 03:32 ET | 100 | 0.6099 |
| 03:39 ET | 100 | 0.61 |
| 03:43 ET | 59472 | 0.603 |
| 03:50 ET | 1900 | 0.6001 |
| 03:56 ET | 100 | 0.61 |
| 03:57 ET | 100 | 0.61 |
| 03:59 ET | 727 | 0.61 |
Jun 3, 2024
DJ BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co., from 12:45PM ET on Monday Jun 03, 2024 by Dow Jones
12:45PM ET on Monday Jun 03, 2024 by Dow Jones
May 30, 2024
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD), from 7:00AM ET on Thursday May 30, 2024 by Dow Jones
7:00AM ET on Thursday May 30, 2024 by Dow Jones
May 29, 2024
DJ BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co., from 10:34AM ET on Wednesday May 29, 2024 by Dow Jones
10:34AM ET on Wednesday May 29, 2024 by Dow Jones
May 28, 2024
Press Release: BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates, from 7:00AM ET on Tuesday May 28, 2024 by Dow Jones
7:00AM ET on Tuesday May 28, 2024 by Dow JonesBioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates, from 7:00AM ET on Tuesday May 28, 2024 by Dow Jones
7:00AM ET on Tuesday May 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioLine RX Ltd | 51.6M | -0.8x | --- |
Dyadic International Inc | 51.5M | -5.8x | --- |
LAVA Therapeutics NV | 48.9M | -1.7x | --- |
Lipocine Inc | 48.0M | -5.4x | --- |
Cue Biopharma Inc | 65.7M | -1.4x | --- |
Kezar Life Sciences Inc | 46.8M | -0.5x | --- |
Company Information
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Contact Information
- Headquarters
- Modi'in Technology Park 2 HaMa'ayan StreetMODIIN, Israel 7177871
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Aharon Schwartz
- Chief Executive Officer
- Philip Serlin
- Chief Financial Officer
- Mali Zeevi
- Vice President - Development
- Ella Sorani
- Vice President-Clinical & Medical Affairs
- Abi Vainstein-Haras
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $51.6M |
|---|---|
Revenue (TTM) | $11.7M |
Shares Outstanding | 79.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.52 |
EPS | $-0.76 |
Book Value | $0.18 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | 4.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -391.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
